ABT
$96.00
Abbott Laboratories
($.81)
(.84%)
ABT
Earnings Whisper ®
N/A
2nd Quarter June 2026
Consensus: $1.28
Revenue: $11.87 Bil
Share
Watch
Guidance announcement made Thursday, April 16, 2026
Latest EPS
Thursday, April 16, 2026
What do you expect when ABT reports earnings?
Where is ABT's stock price going from here?
Analysts
Pivots
Resistance
$98.88
$98.10
$97.05
Support
$95.22
$94.44
$93.39
Description
Abbott Labs discovers, develops, manufactures & sells a diversified line of health care products. Established Pharmaceuticals Division includes branded generics business in the emerging markets. Medical Devices unit includes the diabetes care, vision care & vascular businesses. Diagnostics unit manufactures and markets diagnostic systems and tests in four business lines core laboratory, molecular, point of care and rapid diagnostics. Nutrition unit includes a broad line of pediatric and adult nutritional products. Abbott acquired CFR Pharmaceuticals, Tendyne Holdings, Inc., St. Jude Medical and Alere Inc. On the other hand, Abbott sold its developed markets branded generics pharmaceuticals business to Mylan. Abbott retained the branded generics pharmaceuticals business in emerging markets. Abbott sold its animal health business to Zoetis Inc and divested its vision care business, Medical Optics, to Johnson & Johnson.